We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+38.45%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$617M
AUM Growth
+$270M
Cap. Flow
+$176M
Cap. Flow %
28.52%
Top 10 Hldgs %
38.27%
Holding
109
New
46
Increased
22
Reduced
16
Closed
21

Top Buys

1
ZBH icon
Zimmer Biomet
ZBH
+$15.9M
2
ABT icon
Abbott
ABT
+$12.9M
3
DBVT
DBV Technologies
DBVT
+$8.68M
4
CELG
Celgene Corp
CELG
+$8.12M
5
CYNO
Cynosure, Inc. Class A
CYNO
+$7.79M

Top Sells

1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.1M
2
MDT icon
Medtronic
MDT
+$8.68M
3
BLUE
bluebird bio
BLUE
+$6.15M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$5.68M
5
CNMD icon
CONMED
CNMD
+$5.52M

Sector Composition

1 Healthcare 51.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
26
DELISTED
Sage Therapeutics
SAGE
$8.06M 1.31%
+175,000
New +$7.12M
BCRX icon
27
BioCryst Pharmaceuticals
BCRX
$2.36B
$7.94M 1.29%
1,800,000
+100,000
+6% +$399K
CELG
28
CALL
DELISTED
Celgene Corp
CELG
$7.84M 1.27%
+75,000
New +$8.12M
CYNO
29
DELISTED
Cynosure, Inc. Class A
CYNO
$7.64M 1.24%
+150,000
New +$7.79M
NSTG
30
DELISTED
NanoString Technologies, Inc.
NSTG
$7.49M 1.22%
375,000
+125,000
+50% +$1.98M
AVDL
31
DELISTED
Avadel Pharmaceuticals
AVDL
$7.13M 1.16%
575,000
+225,000
+64% +$2.94M
IOVA icon
32
Iovance Biotherapeutics
IOVA
$2.23B
$6.79M 1.1%
825,000
+125,000
+18% +$1.06M
PACB icon
33
Pacific Biosciences
PACB
$447M
$6.72M 1.09%
+750,000
New +$6.27M
ENTA icon
34
Enanta Pharmaceuticals
ENTA
$400M
$6.65M 1.08%
+250,000
New +$5.81M
IMMU
35
DELISTED
Immunomedics Inc
IMMU
$6.5M 1.05%
2,000,000
+1,000,000
+100% +$2.8M
ACAD icon
36
Acadia Pharmaceuticals
ACAD
$4.38B
$6.36M 1.03%
+200,000
New +$6.78M
NVRO
37
DELISTED
NEVRO CORP.
NVRO
$6.26M 1.02%
60,000
-20,000
-25% -$1.81M
SIOX
38
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.6M 0.91%
50,000
-21,875
-30% -$2.63M
TVTX icon
39
Travere Therapeutics
TVTX
$5.27B
$5.59M 0.91%
+250,000
New +$4.76M
BMRN icon
40
BioMarin Pharmaceuticals
BMRN
$11.5B
$5.55M 0.9%
60,000
-50,000
-45% -$4.71M
IONS icon
41
CALL
Ionis Pharmaceuticals
IONS
$8.99B
$5.5M 0.89%
+150,000
New +$4.69M
QGENF
42
DELISTED
QIAGEN NV
QGENF
$5.49M 0.89%
+200,000
New +$5.49M
HZNP
43
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.44M 0.88%
300,000
+100,000
+50% +$1.95M
ACOR
44
DELISTED
Acorda Therapeutics
ACOR
$5.22M 0.85%
2,083
-625
-23% -$1.86M
AERI
45
DELISTED
Aerie Pharmaceuticals
AERI
$4.72M 0.77%
+125,000
New +$2.76M
BIIB icon
46
Biogen
BIIB
$30.4B
$4.7M 0.76%
15,000
-15,000
-50% -$4.44M
ACRS icon
47
Aclaris Therapeutics
ACRS
$793M
$4.48M 0.73%
+175,000
New +$3.71M
ENTL
48
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$4.44M 0.72%
200,000
+80,000
+67% +$1.5M
PTHN
49
DELISTED
Patheon N.V.
PTHN
$4.3M 0.7%
+275,700
New +$7.55M
HZNP
50
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.08M 0.66%
225,000
-25,000
-10% -$488K
1
2
3 4 5

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Ghost Tree Capital held 109 positions worth $617M, up 78% from $346M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ghost Tree Capital deployed $176M of net new capital in Q3 2016, opening 46 new positions and adding to 22 existing holdings. Its largest new stake was Zimmer Biomet: 128,750 shares worth $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 56% a quarter earlier.

On the sell side, the largest reduction was bluebird bio, an estimated $6.15M trimmed.

  • Ghost Tree Capital's largest Q3 2016 buy was Zimmer Biomet: 128,750 shares worth $16.3M.
  • Ghost Tree Capital added most to Celgene Corp in Q3 2016, an estimated $8.12M increase.
  • Ghost Tree Capital's biggest Q3 2016 reduction was bluebird bio, cutting an estimated $6.15M.
  • Ghost Tree Capital fully exited IVERIC bio, Inc. Common Stock in Q3 2016, selling an estimated $12.1M.
  • Ghost Tree Capital's ten largest holdings make up 38% of its $617M portfolio in Q3 2016.
  • Ghost Tree Capital opened 46 new positions and closed 21 in Q3 2016.
  • Ghost Tree Capital's portfolio value rose 78% quarter-over-quarter to $617M.

Based on Ghost Tree Capital's 13F filing for Q3 2016, filed 14 Nov 2016.